Andrei-mircea Catarig

Soborg, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial.

Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial.

Journal: European heart journal

Published: March 04, 2026

Improvement in Walking Distance With Semaglutide in Smokers With Peripheral Artery Disease: STRIDE Trial Subgroup Analysis.

Improvement in Walking Distance With Semaglutide in Smokers With Peripheral Artery Disease: STRIDE Trial Subgroup Analysis.

Journal: Journal of the American College of Cardiology

Published: July 21, 2025

Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.

Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.

Journal: Journal of the American College of Cardiology

Published: July 07, 2025

Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.

Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.

Journal: Diabetes care

Published: May 08, 2025

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.

Journal: Lancet (London, England)

Published: February 27, 2025

Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs.

Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs.

Journal: Pharmaceutical research

Published: August 30, 2024

Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.

Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.

Journal: European heart journal. Cardiovascular pharmacotherapy

Published: August 06, 2024

Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.

Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.

Journal: Advances in therapy

Published: July 25, 2024

Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study.

Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study.

Journal: Diabetes, obesity & metabolism

Published: May 20, 2024

Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme.

Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme.

Journal: Diabetes, obesity & metabolism

Published: February 01, 2024

Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study.

Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study.

Journal: Diabetologia

Published: March 13, 2023

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.

Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

Published: January 04, 2023

Showing 1-12 of 27

Last Updated: 09/26/2026